You searched for - PharmaLive

New Search

If you are not happy with the results below please do another search

50 search results for:

Tipping point: charting the future of health care

April 18, 2024/in Marketing & Advertising, Therapeutics/by Administrator

Three core trends emerge as pivotal forces driving the healthcare sector forward: strategic responses to economic uncertainty, the accelerated growth in AI investments, and the groundbreaking advancements in next-generation medications. Together, these trends do not merely represent shifts within the health sector; they signal a critical tipping point, one that demands adaptability, foresight, and an unwavering focus on innovation to navigate the future of health care.

Beghou Consulting welcomes John Dawley as adviser

April 18, 2024/in Marketing & Advertising/by Administrator

“Over his impressive career, John has successfully scaled technology solutions for the life sciences industry,” said Beth Beghou, CEO of Beghou Consulting. “I know he is as enthusiastic as we are about helping companies develop agile and patient-centric commercialization models.”

Roche’s Ocrevus achieves near-complete reduction of relapse, lesions in MS

April 18, 2024/in Therapeutics/by BioSpace

Roche subsidiary Genentech on Wednesday released data from the Phase III OCARINA II study, showing that its investigational subcutaneous formulation for Ocrevus (ocrelizumab) strongly reduced relapses and brain lesions in patients with relapsing or primary progressive multiple sclerosis.

Teva, Alvotech secure FDA approval for Stelara biosimilar with early 2025 launch

April 18, 2024/in Therapeutics/by BioSpace

Like its branded reference product, Selarsdi is a subcutaneous injection that can be used to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in pediatric and adult patients. Unlike Stelara, however, Selarsdi is not approved for Crohn’s disease and ulcerative colitis.

German watchdog approves Novo’s acquisition of Cardior Pharmaceuticals

April 18, 2024/in Therapeutics/by Reuters Health

The German cartel office has approved a deal by Denmark’s Novo Nordisk (NOVOb.CO) to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.

Cerevel gets Phase III Parkinson’s win on heels of $8.7B AbbVie acquisition

April 18, 2024/in Therapeutics/by BioSpace

Cerevel Therapeutics reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can significantly improve symptom control in patients with Parkinson’s disease.

Elahere and Keytruda pave way to ADC and ICI strategies in endometrial cancer

April 18, 2024/in R&D, Therapeutics/by Administrator

With continued success, Elahere will not only infiltrate the endometrial cancer market but also pave the way for future treatment strategies with an ADC and immunotherapy combination, says GlobalData.

AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure

April 18, 2024/in R&D, Therapeutics/by Administrator

“The FDA Fast Track Designation for AB-1002 is an important accomplishment for the clinical development of this program and highlights our goal of bringing potentially effective treatments to patients with advanced congestive heart failure,” said Canwen Jiang, MD, PhD, Chief Development Officer and Chief Medical Officer, AskBio.

Most of Lilly’s Mounjaro and Zepbound doses in limited supply, FDA says

April 17, 2024/in Therapeutics/by Reuters Health

According to the agency’s website, most doses of Eli Lilly’s diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand.

CHC names Compliancy Group as a preferred partner for HIPAA compliance

April 17, 2024/in Marketing & Advertising/by Administrator

“Compliancy Group is the first of a cadre of HIPAA compliance resources vetted by the CHC to assist agencies working with healthcare covered entities to navigate the nuances of HIPAA, federal breach notification requirements, and evolving state privacy laws,” said Jim Potter, CHC executive director.